Vyndamax
Vyndamax Uses, Dosage, Side Effects, Food Interaction and all others data.
Vyndamax and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Vyndamax is structurally similar to diflusinal.
Vyndamax was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Vyndamax stabilizes transthyretin tetramers, reducing the amount of monomers available for amyloidogenesis. It has a long duration of action as it is given once daily, and a wide therapeutic window.
Trade Name | Vyndamax |
Availability | Prescription only |
Generic | Tafamidis |
Tafamidis Other Names | Tafamidis, Tafamidisum |
Related Drugs | Vyndamax, Onpattro, Vyndaqel, Amvuttra, patisiran |
Weight | 61mg, meglumine20mg, |
Type | Oral Capsule, Oral Capsule 61mg |
Formula | C14H7Cl2NO3 |
Weight | Average: 308.116 Monoisotopic: 306.980298509 |
Protein binding | Tafamidis 99.9% protein bound in plasma, mostly to transthyretin. |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | Australia, United States, |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Vyndamax is a medication used to treat transthyretin-mediated amyloidosis.
Vyndamax is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.
Vyndamax is also used to associated treatment for these conditions: Cardiomyopathy
How Vyndamax works
Genetic mutations or natural misfolding of transthyretin destabalizes transthyretin tetramers, leading to their dissociation and aggregation in tissues, and disrupting the normal function of these tissues. Vyndamax binds to transthyretin tetramers at the thyroxin binding sites, stabilizing the tetramer, reducing the availability of monomers for amyloidogenesis.
Toxicity
Data regarding overdoses of tafamidis are not readily available. In a clinical trial, some patients were given up to 6 times the normal dose with one reported case of mild hordeolum.
Food Interaction
- Take with or without food.
Vyndamax Drug Interaction
Moderate: bumetanide, rosuvastatin, acetaminophenUnknown: risedronate, aspirin, suvorexant, diphenhydramine, tadalafil, methylcellulose, loratadine, sulfamethoxazole / trimethoprim, colchicine, apixaban, ethanol, ferrous sulfate, metoprolol, tramadol, ascorbic acid, cholecalciferol, metolazone
Vyndamax Disease Interaction
Volume of Distribution
The apparent volume of distribution at steady state is 18.5L.
Elimination Route
Vyndamax reaches a Cmax of 1430.93ng/mL with a Tmax of 1.75h fasted and 4h fed. The AUC of tafamidis is 47,864.31ng*h/mL.
Half Life
The half life of tafamidis is 49h.
Clearance
The oral clearance of tafamidis is 0.263L/h. The apparent total clearance is 0.44L/h.
Elimination Route
A 20mg oral dose of tafamidis is approximately 59% recovered in the feces, largely as unchanged drug. Approximately 22% of a 20mg oral dose is recovered in the urine, mostly as the glucuronide metabolite.
Innovators Monograph
You find simplified version here Vyndamax